Standout Papers

Research criteria for the diagnosis of Alzheimer'... 1990 2026 2002 2014 3.1k
  1. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007)
    Bruno Dubois, Howard Feldman et al. The Lancet Neurology
  2. Alzheimer's disease (2011)
    Clive Ballard, Serge Gauthier et al. The Lancet
  3. Mild cognitive impairment: a concept in evolution (2014)
    R. Petersen, Barbara Caracciolo et al. Journal of Internal Medicine
  4. Variable expression of Parkinson's disease (1990)
    Joseph Jankovic, Michael McDermott et al. Neurology
  5. Apolipoprotein E polymorphism and Alzheimer's disease (1993)
    Judes Poirier, Philìppe Bertrand et al. The Lancet
  6. Vascular cognitive impairment (2003)
    John T. O’Brien, Timo Erkinjuntti et al. The Lancet Neurology
  7. Development of a Functional Measure for Persons With Alzheimer’s Disease: The Disability Assessment for Dementia (1999)
    Isabelle Gélinas, Louise Gauthier et al. American Journal of Occupational Therapy
  8. Dementia in China: epidemiology, clinical management, and research advances (2019)
    Longfei Jia, Meina Quan et al. The Lancet Neurology
  9. Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease (1997)
    N. Bodick, Walter Offen et al. Archives of Neurology
  10. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial (2002)
    Timo Erkinjuntti, Alexander Kurz et al. The Lancet
  11. Vascular Cognitive Impairment (2014)
    John T. O’Brien, Timo Erkinjuntti et al. International Journal of Stroke
  12. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology (2021)
    Nicholas J. Ashton, Tharick A. Pascoal et al. Acta Neuropathologica
  13. Dementia care during COVID-19 (2020)
    Huali Wang, Tao Li et al. The Lancet
  14. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial (2016)
    Serge Gauthier, Howard Feldman et al. The Lancet
  15. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations (2017)
    Zahinoor Ismail, Luis Agüera-Ortíz et al. Journal of Alzheimer s Disease

Immediate Impact

11 by Nobel laureates 23 from Science/Nature 125 standout
Sub-graph 1 of 16

Citing Papers

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout

Works of Serge Gauthier being referenced

Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
2020
Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease
1997 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Serge Gauthier 15085 11678 5997 560 34.5k
Clive Ballard 15559 9813 5064 662 39.6k
Hilkka Soininen 15704 16451 7561 672 39.3k
Richard Mayeux 19443 20883 7254 514 51.2k
Bruno Dubois 18239 14581 12297 409 37.8k
Howard Feldman 13401 12047 4895 230 29.7k
David A. Drachman 16120 13343 7641 165 32.4k
Richard C. Mohs 25201 16180 10444 256 44.1k
Claudia H. Kawas 14872 13353 5583 235 31.3k
Carol Brayne 19317 13130 7308 723 53.7k
Mony J. de Leon 11476 13296 5986 297 30.0k

All Works

Loading papers...

Rankless by CCL
2026